Skip to content
Amgen
-
Amgen targets acute myeloid leukemia with USD840M Dark Blue Therapeutics deal
Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.